200 related articles for article (PubMed ID: 19755754)
1. Investigation into the efficacy and safety of octreotide LAR in Japanese patients with acromegaly: Shizuoka study.
Oki Y; Inoue T; Imura M; Tanaka T; Genma R; Iwabuchi M; Hataya Y; Matsuzawa Y; Iino K; Nishizawa S; Nakamura H
Endocr J; 2009; 56(9):1095-101. PubMed ID: 19755754
[TBL] [Abstract][Full Text] [Related]
2. Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly.
Colao A; Ferone D; Marzullo P; Cappabianca P; Cirillo S; Boerlin V; Lancranjan I; Lombardi G
J Clin Endocrinol Metab; 2001 Jun; 86(6):2779-86. PubMed ID: 11397887
[TBL] [Abstract][Full Text] [Related]
3. Treatment of acromegaly with octreotide-LAR: extensive experience in a Brazilian institution.
Jallad RS; Musolino NR; Salgado LR; Bronstein MD
Clin Endocrinol (Oxf); 2005 Aug; 63(2):168-75. PubMed ID: 16060910
[TBL] [Abstract][Full Text] [Related]
4. Does partial surgical tumour removal influence the response to octreotide-LAR in acromegalic patients previously resistant to the somatostatin analogue?
Jallad RS; Musolino NR; Kodaira S; Cescato VA; Bronstein MD
Clin Endocrinol (Oxf); 2007 Aug; 67(2):310-5. PubMed ID: 17555503
[TBL] [Abstract][Full Text] [Related]
5. Primary medical therapy for acromegaly: an open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin-like growth factor-I, and tumor size.
Bevan JS; Atkin SL; Atkinson AB; Bouloux PM; Hanna F; Harris PE; James RA; McConnell M; Roberts GA; Scanlon MF; Stewart PM; Teasdale E; Turner HE; Wass JA; Wardlaw JM
J Clin Endocrinol Metab; 2002 Oct; 87(10):4554-63. PubMed ID: 12364434
[TBL] [Abstract][Full Text] [Related]
6. Cardiovascular effects of depot long-acting somatostatin analog Sandostatin LAR in acromegaly.
Colao A; Marzullo P; Ferone D; Spinelli L; Cuocolo A; Bonaduce D; Salvatore M; Boerlin V; Lancranjan I; Lombardi G
J Clin Endocrinol Metab; 2000 Sep; 85(9):3132-40. PubMed ID: 10999798
[TBL] [Abstract][Full Text] [Related]
7. A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly.
Mercado M; Borges F; Bouterfa H; Chang TC; Chervin A; Farrall AJ; Patocs A; Petersenn S; Podoba J; Safari M; Wardlaw J;
Clin Endocrinol (Oxf); 2007 Jun; 66(6):859-68. PubMed ID: 17465997
[TBL] [Abstract][Full Text] [Related]
8. Slow-release lanreotide in the treatment of acromegaly: a study in 66 patients.
Verhelst JA; Pedroncelli AM; Abs R; Montini M; Vandeweghe MV; Albani G; Maiter D; Pagani MD; Legros JJ; Gianola D; Bex M; Poppe K; Mockel J; Pagani G
Eur J Endocrinol; 2000 Nov; 143(5):577-84. PubMed ID: 11078980
[TBL] [Abstract][Full Text] [Related]
9. First-line octreotide-LAR therapy induces tumour shrinkage and controls hormone excess in patients with acromegaly: results from an open, prospective, multicentre trial.
Colao A; Pivonello R; Rosato F; Tita P; De Menis E; Barreca A; Ferrara R; Mainini F; Arosio M; Lombardi G
Clin Endocrinol (Oxf); 2006 Mar; 64(3):342-51. PubMed ID: 16487447
[TBL] [Abstract][Full Text] [Related]
10. Forty month follow-up of persistent and difficultly controlled acromegalic patients treated with depot long acting somatostatin analog octreotide.
Yetkin DO; Boysan SN; Tiryakioglu O; Yalin AS; Kadioglu P
Endocr J; 2007 Jun; 54(3):459-64. PubMed ID: 17495423
[TBL] [Abstract][Full Text] [Related]
11. Comparison of octreotide acetate LAR and lanreotide SR in patients with acromegaly.
Chanson P; Boerlin V; Ajzenberg C; Bachelot Y; Benito P; Bringer J; Caron P; Charbonnel B; Cortet C; Delemer B; Escobar-Jiménez F; Foubert L; Gaztambide S; Jockenhoevel F; Kuhn JM; Leclere J; Lorcy Y; Perlemuter L; Prestele H; Roger P; Rohmer V; Santen R; Sassolas G; Scherbaum WA; Schopohl J; Torres E; Varela C; Villamil F; Webb SM
Clin Endocrinol (Oxf); 2000 Nov; 53(5):577-86. PubMed ID: 11106918
[TBL] [Abstract][Full Text] [Related]
12. Time course of GH and IGF-1 levels following withdrawal of long-acting octreotide in acromegaly.
Lorcy Y; Dejager S; Chanson P;
Pituitary; 2000 Nov; 3(3):193-7. PubMed ID: 11383486
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of a slow-release formulation of lanreotide (Autogel) 120 mg) in patients with acromegaly previously treated with octreotide long acting release (LAR): an open, multicentre longitudinal study.
Ronchi CL; Boschetti M; Degli Uberti EC; Mariotti S; Grottoli S; Loli P; Lombardi G; Tamburrano G; Arvigo M; Angeletti G; Boscani PF; Beck-Peccoz P; Arosio M;
Clin Endocrinol (Oxf); 2007 Oct; 67(4):512-9. PubMed ID: 17555511
[TBL] [Abstract][Full Text] [Related]
14. Systematic dose-extension of octreotide LAR: the importance of individual tailoring of treatment in patients with acromegaly.
Turner HE; Thornton-Jones VA; Wass JA
Clin Endocrinol (Oxf); 2004 Aug; 61(2):224-31. PubMed ID: 15272918
[TBL] [Abstract][Full Text] [Related]
15. Octreotide long-acting release (LAR): a review of its use in the management of acromegaly.
McKeage K; Cheer S; Wagstaff AJ
Drugs; 2003; 63(22):2473-99. PubMed ID: 14609359
[TBL] [Abstract][Full Text] [Related]
16. Predicting therapeutic response and degree of pituitary tumour shrinkage during treatment of acromegaly with octreotide LAR.
Jenkins PJ; Emery M; Howling SJ; Evanson J; Besser GM; Monson JP
Horm Res; 2004; 62(5):227-32. PubMed ID: 15477693
[TBL] [Abstract][Full Text] [Related]
17. Efficacy, safety, and pharmacokinetics of sustained-release lanreotide (lanreotide Autogel) in Japanese patients with acromegaly or pituitary gigantism.
Shimatsu A; Teramoto A; Hizuka N; Kitai K; Ramis J; Chihara K
Endocr J; 2013; 60(5):651-63. PubMed ID: 23337477
[TBL] [Abstract][Full Text] [Related]
18. Optimizing medical therapy of acromegaly: beneficial effects of cabergoline in patients uncontrolled with long-acting release octreotide.
Jallad RS; Bronstein MD
Neuroendocrinology; 2009; 90(1):82-92. PubMed ID: 19439914
[TBL] [Abstract][Full Text] [Related]
19. Octreotide LAR vs. surgery in newly diagnosed patients with acromegaly: a randomized, open-label, multicentre study.
Colao A; Cappabianca P; Caron P; De Menis E; Farrall AJ; Gadelha MR; Hmissi A; Rees A; Reincke M; Safari M; T'Sjoen G; Bouterfa H; Cuneo RC
Clin Endocrinol (Oxf); 2009 May; 70(5):757-68. PubMed ID: 19178516
[TBL] [Abstract][Full Text] [Related]
20. Sandostatin LAR in acromegaly: a 6-week injection interval suppresses GH secretion as effectively as a 4-week interval.
Biermasz NR; van den Oever NC; Frölich M; Arias AM; Smit JW; Romijn JA; Roelfsema F
Clin Endocrinol (Oxf); 2003 Mar; 58(3):288-95. PubMed ID: 12608933
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
